The US Food and Drug Administration (FDA) has cleared Roche’s respiratory pathogen testing panel to assist labs and clinicians in identifying the cause of infections as peak respiratory season begins.
The test, dubbed the cobas eplex respiratory pathogen panel 3 (RP3), is designed to rapidly identify the cause of a respiratory infection from a nasopharyngeal swab via the automated cobas explex system – thus allowing clinicians to identify and administer the best care in a shorter space of time.